12.05
+0.445(+3.83%)
Currency In USD
| Previous Close | 11.61 |
| Open | 11.6 |
| Day High | 12.28 |
| Day Low | 11.52 |
| 52-Week High | 13.41 |
| 52-Week Low | 4.02 |
| Volume | 846,780 |
| Average Volume | 1.08M |
| Market Cap | 656.88M |
| PE | 9.22 |
| EPS | 1.32 |
| Moving Average 50 Days | 9.97 |
| Moving Average 200 Days | 7.43 |
| Change | 0.56 |
If you invested $1000 in Emergent BioSolutions Inc. (EBS) 10 years ago, it would be worth $322.47 as of December 04, 2025 at a share price of $12.17. Whereas If you bought $1000 worth of Emergent BioSolutions Inc. (EBS) shares 5 years ago, it would be worth $147 as of December 04, 2025 at a share price of $12.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
GlobeNewswire Inc.
Nov 18, 2025 1:00 PM GMT
GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
GlobeNewswire Inc.
Nov 12, 2025 9:01 PM GMT
GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and i
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respondGAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) --